We further demonstrated that the lead compounds have the potential to inhibit proliferation of androgen-receptor-positive prostate-cancer cells (LNCaP) and their inhibitory potential is enhanced in a co-treatment regimen with known PI3K, AKT and androgen receptor inhibitors (LY294002, AKT1/2 and Flutamide, respectively). Here, AKT1 is linked to prostate carcinoma.